medigraphic.com
Colegio de Medicina Interna de México.

2015, Número 6

<< Anterior Siguiente >>

Med Int Mex 2015; 31 (6)


Degludec: insulina de larga duración

Alexanderson-Rosas EG, Llamas-Moreno JF, Castro-Martínez MG, Frenk-Barón P, Romo-Pérez OA, Mena-Madrazo JA

Idioma: Español
Referencias bibliográficas: 31
Paginas: 709-718
Archivo PDF: 505.78 Kb.


RESUMEN

La insulina degludec es una insulina basal análoga de nueva generación con duración de acción ultraprolongada que tiene un perfil farmacocinético y farmacodinámico único que la hace superior a otras insulinas basales administradas durante mucho tiempo, como las primeras insulinas humanas. Algunas ventajas observadas con la insulina degludec son la reducción importante de hipoglucemia confirmada y particularmente de la hipoglucemia nocturna. Este efecto prolongado con una sola aplicación y la flexibilidad en su administración también son destacables.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care 2010;33:240-245.

  2. Peyrot M, Barnett AH, Meneghini LF, et al. Diabet Med 2012;29:682-689.

  3. Biester T, Blaesig S, Remus K, et al. Insulin degludec's ultralong pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes 2014;15:27-33.

  4. Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013;30:1293-1297.

  5. Donnelly LA, Morris AD, Evans JM, DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345-350.

  6. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-1507.

  7. Goldman-Levine JD, Patel DK, Schnee DM. Insulin degludec: a novel basal insulin analogue. Ann Pharmacother 2013;47:269-277.

  8. Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-totarget trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536-2542.

  9. Gough SC, Harris S, Woo V, et al. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab 2013;15:301-309.

  10. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-1504.

  11. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-864.

  12. Heise T, Nosek L, Bøttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-950.

  13. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-1620.

  14. Philips JC, Scheen A. Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag 2006;2:277-283.

  15. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultralong- acting basal insulin. Pharm Res 2012;29:2104-2114.

  16. Kalra S, Baruah MP, Niazi AK. Degludec: a novel basal insulin. Recent Pat Endocr Metab Immune Drug Discov 2012;6:18-23.

  17. Kalra S. Insulin degludec: a significant advancement in ultralong-acting basal insulin. Diabetes Ther 2013;4:167-173.

  18. Kiss I, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet 2014;53:175-183.

  19. Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs Aging 2014;31:47-53.

  20. Kupčová V, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig 2014;34:127-133.

  21. Maiorino MI, Petrizzo M, Capuano A, et al. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes? Expert Opin Biol Ther 2014;14:799-808.

  22. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98:1154-1162.

  23. Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858-864.

  24. Nasrallah SN, Reynolds LR. Insulin degludec, the new generation basal insulin or just another basal insulin? Clin Med Insights Endocrinol Diabetes 2012;5:31-37.

  25. Onishi Y, Iwamoto Y, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig 2013;4:605-612.

  26. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública, 2006.

  27. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther 2011;13:S103-S108.

  28. Sorli C, Warren M, Oyer D, et al. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a metaanalysis of phase IIIa trials. Drugs Aging 2013;30:1009-1018.

  29. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.

  30. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011;377:924-931.

  31. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464-2471.




2020     |     www.medigraphic.com